94 related articles for article (PubMed ID: 9719952)
1. [Analyses of p53 mutations in breast cancers with a combined use of yeast functional assay and immunohistochemical staining].
Takahashi M
Hokkaido Igaku Zasshi; 1998 May; 73(3):275-86. PubMed ID: 9719952
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
[TBL] [Abstract][Full Text] [Related]
3. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
5. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
6. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
7. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
8. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers.
Shiao YH; Palli D; Caporaso NE; Alvord WG; Amorosi A; Nesi G; Saieva C; Masala G; Fraumeni JF; Rice JM
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):631-3. PubMed ID: 10868700
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
10. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
11. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of nuclear accumulation of p53 protein with mutations in the p53 gene on the tissues of human breast cancer].
Fan P; Wu Z; Cha X; Wang X; Wang S
Zhonghua Wai Ke Za Zhi; 1998 Nov; 36(11):655-7. PubMed ID: 11825490
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.
Watanabe J; Nishiyama H; Okubo K; Takahashi T; Toda Y; Habuchi T; Kakehi Y; Tada M; Ogawa O
Urology; 2004 May; 63(5):989-93. PubMed ID: 15135005
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
15. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Casey G; Lopez ME; Ramos JC; Plummer SJ; Arboleda MJ; Shaughnessy M; Karlan B; Slamon DJ
Oncogene; 1996 Nov; 13(9):1971-81. PubMed ID: 8934544
[TBL] [Abstract][Full Text] [Related]
16. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
17. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
18. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of p53 exon 4 mutations in soft tissue sarcoma.
Das P; Kotilingam D; Korchin B; Liu J; Yu D; Lazar AJ; Pollock RE; Lev D
Cancer; 2007 Jun; 109(11):2323-33. PubMed ID: 17429838
[TBL] [Abstract][Full Text] [Related]
20. Improving the detection of p53 mutations in breast cancer by use of the FASAY, a functional assay.
Duddy PM; Hanby AM; Barnes DM; Camplejohn RS
J Mol Diagn; 2000 Aug; 2(3):139-44. PubMed ID: 11229518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
